ST8SIA4 is a sialyltransferase that catalyzes the transfer of sialic acid onto terminal sialic acid residues through alpha-2,8-linkages, primarily modifying N-linked glycans on proteins including NCAM1, FETUB, and AHSG 123. The enzyme preferentially accepts alpha-2,3-linked sialic acids over alpha-2,6-linked substrates 4. ST8SIA4 synthesizes polysialic acid (PSA) chains that regulate cell-cell interactions with both attractive and repulsive properties distinct from those produced by ST8SIA2 3. In disease contexts, ST8SIA4 demonstrates opposing roles depending on tissue type. In demyelinating diseases, ST8SIA4 delays oligodendrocyte differentiation and impairs myelin repair, with genetic deletion paradoxically accelerating remyelination 5. Conversely, in cancers, elevated ST8SIA4 promotes pathogenic processes. In breast cancer, BRCA1 deficiency activates TGFβ-ST8SIA4 signaling, increasing PSA accumulation that creates an immunosuppressive microenvironment and facilitates metastasis and immunotherapy resistance 6. ST8SIA4 is post-transcriptionally regulated by multiple miRNAs: miR-146a/b downregulate it to promote thyroid carcinoma progression 7, while miR-181c suppresses it to restore chemosensitivity in leukemia 8. The MALAT1/miR-26a/26b/ST8SIA4 axis also regulates breast cancer cell invasion and migration 9. ST8SIA4-derived lncRNAs serve as biomarkers for lung cancer diagnosis 10.